EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access

Natural history of HPV-16 E6 serology among cancer-free men in a multicenter longitudinal cohort study

Jaimie Z Shing iD, Anna R Giuliano iD, Nicole Brenner, Birgitta Michels iD, Allan Hildesheim iD, Sudhir Srivastava iD, Bradley A Sirak iD, John Schussler iD, Danping Liu iD, Wendy Wang, Tim Waterboer iD, Aimée R Kreimer iD

JNCI: Journal of the National Cancer Institute · 2025

DOI: 10.1093/jnci/djae326 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Jaimie Z Shing und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20850, United States. Hauptthemen laut MEDLINE: Oncogene Proteins, Viral, Repressor Proteins, Human papillomavirus 16, Papillomavirus Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, Intramural Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Human papillomavirus (HPV) type 16 E6 protein seropositivity accurately predicts oropharyngeal squamous cell carcinoma risk decades before diagnosis; but the biomarker’s translational potential is unknown. To inform considerations for oropharyngeal squamous cell carcinoma screening, we described HPV-16 E6 seroprevalence, predictors, and kinetics among cancer-free men.

Methods

In a cohort study in Brazil, Mexico, and the United States, we calculated HPV-16 E6 seropositivity (median fluorescence intensity > 1000), measured by multiplex serology, in cancer-free men. We assessed HPV-16 E6 seropositivity predictors using logistic regression, adjusting for country, age, sexual orientation, and lifetime number of sexual partners. Among HPV-16 E6 seropositive men, we retrieved all available retrospective serum samples and described temporal HPV-16 E6 antibody patterns.

Results

Of 3997 men, 14 had HPV-16 E6 antibodies detected (seroprevalence = 0.35%, 95% CI = 0.19% to 0.59%; median fluorescence intensity = 2407 [IQR = 1325-5986]). Older age was associated with increased odds of HPV-16 E6 seropositivity (50-84 years vs 18-29 years odds ratio = 16.61, 95% CI = 2.20 to 417.03). Serum from 11 of the 14 seropositive men retested positive; 6 men had median fluorescence intensity above 5000, of whom 2 had median fluorescence intensity greater than 10 000. Seven men had 3 or more years of follow-up; all were persistently seropositive for 3 years. One man was seropositive for 9 years but seroreverted at his exit visit. Oral HPV-16 DNA (prevalence = 1.13%) was associated with HPV-16 E6 seropositivity (odds ratio = 16.87, 95% CI = 3.35 to 69.55), but oral HPV-16 DNA positivity was not persistent over follow-up, even when HPV-16 E6 antibodies were persistently detected.

Conclusion

Although HPV-16 E6 seropositivity is rare, it is generally stable once detected; thus, HPV-16 E6 antibodies may be an informative biomarker of HPV-driven oropharyngeal squamous cell carcinoma. Few men seroreverted following HPV-16 E6 seropositivity but remained close to the seropositivity cutoff; thus, cancer risk among these men is less clear.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncogene Proteins, ViralRepressor ProteinsHuman papillomavirus 16Papillomavirus InfectionsOropharyngeal NeoplasmsAntibodies, ViralCarcinoma, Squamous CellHumansMaleMiddle AgedLongitudinal StudiesAgedAdultSeroepidemiologic StudiesUnited StatesBrazilMexicoRetrospective Studies

Substanzen

Oncogene Proteins, ViralE6 protein, Human papillomavirus type 16Repressor ProteinsAntibodies, Viral

Autor:innen und Institutionen

  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20850, United States.
  • Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL 33612, United States.
  • Division of Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
  • Information Management Services, Silver Spring, MD 20705, United States.

ORCID-Profile: Jaimie Z Shing, Anna R Giuliano, Birgitta Michels, Allan Hildesheim, Sudhir Srivastava, Bradley A Sirak, John Schussler, Danping Liu, Tim Waterboer, Aimée R Kreimer

Förderung

  • NCI NIH HHS
  • NIH HHS
  • Intramural Research Program
  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Shing, J. Z., Giuliano, A. R., Brenner, N., Michels, B., Hildesheim, A., Srivastava, S., Sirak, B. A., Schussler, J., Liu, D., Wang, W., Waterboer, T., & Kreimer, A. R. (2025). Natural history of HPV-16 E6 serology among cancer-free men in a multicenter longitudinal cohort study. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae326

Vancouver

Shing JZ, Giuliano AR, Brenner N, Michels B, Hildesheim A, Srivastava S, et al. Natural history of HPV-16 E6 serology among cancer-free men in a multicenter longitudinal cohort study. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djae326

BibTeX
@article{Shing2025,
  author = {Shing, Jaimie Z and Giuliano, Anna R and Brenner, Nicole and Michels, Birgitta and Hildesheim, Allan and Srivastava, Sudhir and Sirak, Bradley A and Schussler, John and Liu, Danping and Wang, Wendy and Waterboer, Tim and Kreimer, Aimée R},
  title = {Natural history of HPV-16 E6 serology among cancer-free men in a multicenter longitudinal cohort study},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2025},
  doi = {10.1093/jnci/djae326}
}
Kostenlos starten →